Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
-- 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing tab‑cel® Phase 3 studies -- An overall response rate (ORR) of 55 and 82 percent was observed in this subgroup of patients with EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT) and solid organ transplant (SOT), respectively -- Estimated 2-year overall survival (OS) in this subgroup was 79 and 81 percent for HCT and SOT, respectively -- Atara to present additional findings describing the hospitalization burden of patients with EBV+ PTLD -- Atara’s Moffitt Cancer Center collaborators to present two ASH abstracts detailing next-generation CAR T technologies
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it will present long-term tab-cel® (tabelecleucel) clinical outcomes from a multicenter Expanded Access Protocol (EAP) study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD). These results, along with findings described in three additional abstracts, will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, to be held December 7-10, 2019, in Orlando, Florida.
“I am pleased with the tab-cel® long-term clinical outcomes for patients with EBV+ PTLD we continue to observe in our EAP study,” said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics. “The well-tolerated safety profile, high response rate and durable 2-year survival data are consistent with our previous tab‑cel® clinical experience and reinforces our confidence in tab-cel® as a potentially transformative off-the-shelf, allogeneic T-cell immunotherapy for this often-deadly ultra-rare cancer.”
Twenty-six EBV+ PTLD patients who failed prior rituximab treatment regimens were enrolled in a tab‑cel® EAP study (EAP-201) as of June 2018, after which EAP-201 was amended to focus on expanded access for patients with EBV+ PTLD and other EBV+ diseases who are not eligible for Atara’s ongoing tab‑cel® Phase 3 studies (EAP-901, NCT02822495 ). The findings presented here are as of June 3, 2019. Consistent with prior studies, no tab-cel® related adverse events leading to discontinuation or death occurred.
A subgroup of 22 EAP-201 EBV+ PTLD patients with adequate ECOG performance status, no CNS disease and no PTLD-related ventilatory support, would have likely met the eligibility criteria for Atara’s ongoing tab‑cel® Phase 3 studies.
The overall response rate (ORR) for patients in this EAP-201 subgroup with EBV+ PTLD following HCT (n=11) and SOT (n=11) was 55 and 82 percent with an estimated two-year overall survival of 79 and 81 percent, respectively.
For all EBV+ PTLD patients enrolled in EAP-201, the ORR was 50 and 83 percent for HCT (n=14) and SOT (n=12), respectively.
Atara will also present additional findings describing the hospitalization burden of patients with EBV+ PTLD following SOT who failed first-line rituximab or rituximab plus chemotherapy.
In addition, Atara’s Moffitt Cancer Center collaborators will present two abstracts detailing next-generation CAR T technologies, licensed exclusively to Atara, and designed to enhance persistence while reducing susceptibility to exhaustion and suppressive immune microenvironments.
Details of the ASH presentations and abstracts are as follows:
Abstract 4071: Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program Poster Presentation Date and Time: Monday, December 9, 6:00 - 8:00 p.m. ESTSession Title: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphoma) – Results from Prospective Clinical Trials: Poster IIILocation: Orange County Convention Center, Hall BAuthors: Susan Prockop, M.D.1, Ran Reshef, M.D.2, Donald E. Tsai, M.D., Ph.D.3, Nancy Bunin, M.D.4, Rolla Abu-Arja, M.D.5, Kris Michael Mahadeo, M.D.6, Wen-Kai Weng, M.D., Ph.D.7, Koen Van Besien, M.D., Ph.D.8, David Loeb, M.D., Ph.D.9, Sunita Dwivedy Nasta, M.D.10, Eneida R. Nemecek, M.D., M.B.A., M.S.11, Minoti Hiremath, MBBS, Ph.D.12, Susan Yue, M.D.13, Yan Sun, Ph.D.13, Willis H Navarro, M.D.12 and Sarah Nikiforow, M.D., Ph.D.14 Affiliations: 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Columbia University Irving Medical Center, New York, NY; 3Loxo Oncology, Stamford, CT; 4Children’s Hospital of Philadelphia, Philadelphia, PA; 5Nationwide Children’s Hospital, Columbus, OH; 6MD Anderson Cancer Center, Houston, TX; 7Division of Blood and Marrow Transplantation, Department of Medicine, Stanford Univ. School of Med., Stanford, CA; 8Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY; 9Montefiore, Bronx, NY; 10University of Pennsylvania, Philadelphia; 11Pediatric Hematology/Oncology & Bone Marrow Transplantation, OHSU Knight Cancer Institute Doernbecher Children’s Hospital, Portland, OR; 12Atara Biotherapeutics, South San Francisco, CA; 13Atara Biotherapeutics, Thousand Oaks, CA; 14Dana-Farber Cancer Institute, Boston, MA
Abstract 65: Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+ PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD RegistryOral Presentation Date and Time: Saturday, December 7, 8:30 a.m. ESTSession Title: 902. Health Services Research – Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of LifeLocation: Orange County Convention Center, W308Authors: Heiner Zimmermann, M.D.1, Hairong Xu, M.D., Ph.D.2, Arie Barlev, Pharm.D.3, Yang Zhang, Ph.D.2, Dhanalakshmi Thirumalai2, Crystal Watson, M.S.3 and Ralf Ulrich Trappe, M.D.1Affiliations: 1Internal Medicine II: Hematology and Oncology, Diako Hospital, Bremen, Germany; 2Atara Biotherapeutics, Inc, Thousand Oaks, CA; 3Atara Biotherapeutics, Inc, South San Francisco, CASummary: Approximately one-half of PTLD patients treated with rituximab, currently first-line therapy for PTLD, are relapsed or refractory to treatment. This review of the German PTLD registry database showed a substantial hospitalization burden for patients failing rituximab treatment, accounting for approximately 20% of patients’ hospitalization time after initial PTLD diagnosis with approximately 10% of the time spent in the ICU.
Abstract 5826: The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States; A Comprehensive Literature ReviewPresentation Date and Time: N/A; will appear in the November supplemental online-only issue of BloodAuthors: Crystal Watson, M.S. 1, Arie Barlev, Pharm.D. 1, Jodie Worrall1, Steve Duff, M.S.3, Rachel Beckerman, Ph.D.2Affiliations: 1Atara Biotherapeutics, Inc, South San Francisco, CA; 2Maple Health Group, New York, NY; 3Veritas Health Economic Consulting, Carlsbad, CA
Abstract 867: Mutation of the CD28 Costimulatory Domain Confers Enhanced CAR T Cell FunctionOral Presentation Date and Time: Monday, December 9, 5:00 p.m. ESTSession Title: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: New ApproachesLocation: Orange County Convention Center, W224ABEFAuthors: Justin C Boucher1, Gongbo Li1, Hiroshi Kotani1, Maria L Cabral2, Dylan Morrissey3, Sae Bom Lee1,4, Kristen Spitler1, Nolan Beatty1,4, Bishwas Shrestha1, Bin Yu1, Aslamuzzaman Kazi5, Xuefeng Wang6, Said M Sebti5, Marco L Davila1,3Affiliations: 1Department of Blood & Marrow Transplant and Cellular Immunotherapy, Division of Clinical Science, H. Lee Moffitt Cancer Center, Tampa, FL; 2Department of Cell Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, University of South Florida, Tampa, FL; 3Morsani College of Medicine, University of South Florida Health, Tampa, FL; 4Cancer Biology PhD Program, University of South Florida, Tampa, FL; 5Drug Discovery Program, H. Lee Moffitt Cancer Center, Tampa, FL; 6Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FLSummary: Current generation Chimeric antigen receptors (CARs) utilizing CD28 co-stimulatory domains have been reported to drive high levels of T cell activation that also lead to exhaustion and shortened persistence. Three signaling subdomains present on CD28 differentially regulate this drive towards exhaustion. Using a combination of in vitro and in vivo genomic studies, this study demonstrates CAR T cells using a modified version of CD28, with tailored signaling driven through the PYAP (mut06) subdomain, optimizes CAR T cell signaling by lowering transcription factors that drive exhaustion.
Abstract 4438: MDSC Suppression of CAR T cell can be Reduced by Targeted Signaling DisruptionPoster Presentation Date and Time: Monday, December 9, 6:00 - 8:00 p.m. ESTSession Title: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster IIILocation: Orange County Convention Center, Hall BAuthors: Estelle V Cervantes1, Justin C Boucher2, Sae Bom Lee2,3, Kristen Spitler2, Kayla Reid2, Marco L Davila1,2Affiliations: 1Morsani College of Medicine, University of South Florida, Tampa, FL, 33612; 2Department of Blood & Marrow Transplant and Cellular Immunotherapy, Division of Clinical Science, H. Lee Moffitt Cancer Center, Tampa, FL, 33612; 3Cancer Biology PhD Program, University of South Tampa, Tampa, FL, 33612Summary: CAR T persistence is one of the challenges faced by CAR T cell therapy. Myeloid derived suppressor cells (MDSCs) function as key contributors to preventing persistence of CAR T cells. Data from this study show MDSCs can suppress CAR T cell function when present in vitro, including during CAR T production, as demonstrated by reductions in CAR T cell activation and cytotoxicity. CAR T cells expressing an optimized CD28 co-stimulatory domain (mut06) were less susceptible to the suppressive effects of MDSCs in vitro and in vivo. These data support that mut06 CARs may improve activity and persistence in the presence of MDSCs and may also improve CAR T production in vitro by overcoming the effects of MDSCs.
About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. ( @Atarabio ) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
Forward-Looking StatementsThis press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the potential impact of tab-cel®; and the results from Atara’s ongoing tab-cel® EAP study. These forward-looking statements are subject to risks and uncertainties, including those discussed in Atara Biotherapeutics’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
INVESTOR & MEDIA CONTACT:
John Craighead, Ph.D.Vice President, Investor Relations & Corporate CommunicationsAtara Biotherapeutics650-410-3012 firstname.lastname@example.org